Over the last 10 years, the pharmaceutical industry’s attention has shifted away from the industry stalwart of chemistry and small molecules, to focus on the new biologics gold rush of monoclonal antibodies and recombinant proteins. As a result, the chemical API market for western contract manufacturers as a whole suffered decline and consolidation throughout 2005-2015. Many custom manufacturing organizations (CMOs) shifted focus to higher-value biologics manufacturing, mothballing plants or exiting the business completely. Encouragingly over the last few years, this vogue appears to have subsided, and attention now appears to be back with small molecules therapeutics demonstrated by a growing worldwide demand and several blockbusters launched or pending launch over the past few years and near future.
As many industry experts will acknowledge, quantification of the small molecule API industry is difficult with most reviews or analyses either misleading or lacking sufficient depth to be useful. In this webinar, fine chemicals industry expert, Jan Ramakers, as well as Cambrex’s marketing intelligence group, will use their compiled and individual data to outline and review the pharmaceutical market from the vantage point of chemical molecules and present an overview of the API market. This presentation will attempt to present a balanced review of the competitive CMO landscape for small molecule API manufacturing and show how Cambrex is positioned within the CMO market.
Join our featured speakers as they explore this small molecule resurgence and showcase commitment to the chemical API market.
Dr. Matthew Moorcroft, VP of Global Marketing and Communications, Cambrex
Matt is the Vice President of Global Marketing and Communications for Cambrex. Prior to joining Cambrex, he worked for Lonza and held a number of roles including Head of Global Marketing, VP Generics and Biosimilars, and Head of Strategy, Pharmaceuticals and Biologics. After gaining experience in the custom development & manufacturing business, he developed models for biosimilars and generic drug products. He has over 10 years of commercial and scientific experience in the Pharmaceutical, biotechnology and chemical industry covering both innovative and generic medicines. Matt graduated with a Ph.D. in chemistry from the University of Oxford.Message Presenter
Dr. Jan Ramakers, Director, Jan Ramakers Fine Chemical Consulting Group
Jan is the director of Jan Ramakers Fine Chemical Consulting Group. He spent 16 years at DSM, in various positions at R&D, marketing, business development, business intelligence and strategy development. Following that, he set up and ran a fine chemical consultancy practice for Wood Mackenzie. In 1999, he created Jan Ramakers Fine Chemical Consulting Group, focused on providing tailor-made analyses of all aspects of the global fine chemicals and life sciences business, including strategy development and M&A assistance. All together Jan has had almost 35 years involvement with the industry, of which 5 years in R&D, 11 years in business research and business development, and 18 years as a business consultant.Message Presenter
Who Should Attend?
Sourcing, procurement, project managers, supplier manager, contract manufacturing managers, R&D chemists, process chemists, CEOs, CFOs, COOs
Cambrex is a global, innovative life sciences company that provides products and services to accelerate the development and commercialization of small molecule active Pharmaceutical ingredients (APIs). Cambrex has manufacturing facilities in the US, Europe and, India and R&D centers in Europe. Cambrex is headquartered in East Rutherford, New Jersey, USA.
Cambrex offers APIs, advanced intermediates and enhanced drug delivery products for branded and generic Pharmaceuticals. Custom development and manufacturing capabilities include biocatalysis, high potency APIs, high energy chemical synthesis, controlled substances and drug product formulations.
Jan Ramakers Fine Chemical Consulting Group
Jan Ramakers Fine Chemical Consulting Group, established in 1999, is focused on analyzing and benchmarking the global fine chemical industry. The company provides tailor-made confidential consultancy services including market, product, industry, competitor analysis, company strategy analysis, assistance in M&A and due diligence.
With more than 25 years of experience in analyzing the global fine chemicals business, Jan has undertaken confidential consultancy studies for many leading companies in the fine chemical and related industries around the world, as well as for leading investment banks and private equity companies.
For more information visit http://www.jan-ramakers.com/.